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Aim. The aim of this narrative review was to explore the potential contributions of CAM to reduce antibiotic use. Methods.
We searched PubMed, Embase, and Cochrane Database of Systematic Reviews with a specific, limited set of search terms and
collected input from a group of expert CAM researchers to answer the question: What is known about the contribution of CAM
health and health promotion concepts, infection prevention, and infection treatment strategies to reduce antibiotic use? Results.
The worldview-related CAM health concepts enable health promotion oriented infection prevention and treatment aimed at
strengthening or supporting the self-regulating ability of the human organism to cope with diseases. There is some evidence that
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2 Evidence-Based Complementary and Alternative Medicine
the CAM concepts of health (promotion) are in agreement with current conceptualization of health and that doctors who practice
both CAM and conventional medicine prescribe less antibiotics, although selection bias of the presented studies cannot be ruled
out. There is some evidence that prevention and some treatment strategies are effective and safe. Many CAM treatment strategies
are promising but overall lack high quality evidence. Conclusions. CAM prevention and treatment strategies may contribute to
reducing antibiotic use, but more rigorous research is necessary to provide high quality evidence of (cost-)effectiveness.
1. Introduction
Resistance to antibiotics is a complex and growing, inter-
national public health problem [1, 2]. Worldwide strategies
to control antimicrobial resistance (AMR) and its major
consequences (increased mortality, economic impact) are
being developed [3, 4]. Currently these strategies appear to be
insufficient, as, for example, demonstrated by the unchanged
average European consumption rates of antibiotics during
the years 2011–2014 [4], although in the UK in 2015 for the
first time fewer antibiotics were being prescribed by GPs and
clinicians across all healthcare settings than in 2014 [5].
Among others, finding alternatives for antibiotics [2,
6], alone or as part of a delayed prescription approach,
may provide a good strategy to optimize appropriate use of
antibiotics, meeting both doctors’ and patients’ needs [7–
9]. Alternative nonantibiotic strategies (for symptom relief
and/or fighting bacteria) that are currently being studied are,
among others, phage therapy, antibodies, immune stimula-
tion, lysins, probiotics, and peptides [2].
At the moment, formal policies advising on the need
for alternative strategies to antibiotics do not include the
study and/or application of complementary and alternative
(CAM) therapies for symptom relief and/or treatment of
infections and CAM preventive strategies to reduce the
use of antibiotics, although observational studies in Europe
have shown that CAM practices and hospitals may have
lower antibiotic prescription rates compared to conventional
practices [10], due to additional strategies regarding pre-
vention and treatment of infections [11]. In this article we
use the term CAM, although elsewhere terms as traditional
and complementary medicine [12] or complementary and
integrative medicine [13] are used.
Given the mismatch between the urgent need for nonan-
tibiotic strategies and the lack of use of CAM strategies
embedded in current conventional policies and clinical prac-
tice, we performed a narrative review to determine what
is known about the contribution of CAM to help reduce
antibiotic use.
2. Material and Methods
2.1. Research Questions
(1) What are the worldview differences between CAM
and conventional medicine, relevant for prevention
and treatment of infections and the AMR problem?
(2) What are the hypothesized CAM contributions to
reduce antibiotic use?
(3) Is there evidence
(a) that supports the proposition that CAMpreven-
tion and treatment strategies can lead to the pre-
scription and consumption of fewer antibiotics?
(b) that CAM prevention and treatment strategies
are effective and safe?
2.2. Design. We chose to perform a narrative review based
on (1) searches in three databases with a specific, limited set
of search terms and (2) input from CAM (research) experts,
in order to get a first broad overview of the domain of
(possible) contributions of CAM to reduce antibiotic use.
Based on the results of this broad narrative review, more
methodologically rigorous scoping reviews and/or systematic
reviews on subareas of this scientific field can and must be
performed.
2.3. Identification of Relevant Studies. Searches were per-
formed in PubMed, Embase, and the Cochrane Database of
Systematic Reviews (from onset to June 2017).
Search terms used for PubMed and Embase were “health
concept”, “prevention AND infection”, “lifestyle AND infec-
tion”, “treatment AND infection”, “antibiotic prescription”,
“antibiotic consumption”, each in combinationwith each of the
following search terms for CAM: “complementary medicine”,
“alternative medicine”, “herbal”, “ayurveda OR ayurvedic”,
“homeopathy OR homeopathic”, “TCM OR traditional Chi-
nese medicine”, “anthroposophy OR anthroposophic” (for
example, “health concept” AND “complementary medicine”;
“health concept” AND “alternative medicine”, “health con-
cept” AND “herbal”, etcetera).
Search keywords used for the Cochrane Database of
Systematic Reviews were “alternative medicine AND preven-
tion”, “complementary medicine AND prevention”, “comple-
mentary medicine AND infection”, “herbal AND infection”,
“ayurveda OR ayurvedic”, “homeopathy OR homeopathic”,
“TCM OR traditional Chinese medicine”, “TCM OR tra-
ditional Chinese medicine AND infection”, “anthroposophy
OR anthroposophic”.
2.4. Study Selection. The inclusion criteria used in the narra-
tive review were as follows:
(i) Main research domain:
(a) CAM or IM (mandatory)
(ii) Research topics (one research topic is mandatory):
(a) Worldview
(b) Health (promotion) concept
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(c) Antibiotic prescription
(d) Antibiotic consumption
(e) Prevention of infection
(f) Treatment of infection
The exclusion criteria in this study were as follows:
(i) Only conventional prevention or treatment strategies
for infections
(ii) CAM/IM for noninfection indications
Study collections were exported to Excel and duplicates were
removed. Selection of relevant papers was carried out in two
stages and both stages were performed independently by two
reviewers. In the first stage, both reviewers read the titles and
the abstracts to select potentially relevant papers according to
the inclusion criteria. Disagreements were resolved through
discussion and consensus with the other review author. In
the second stage, the full texts of the included articles were
evaluated.
2.5. Input from CAM Experts. An international group of
CAM clinical and/or research experts was invited for one
or two workshops (25/26 January 2017 and 16/17 February
2017) in Frankfurt (Germany), in which, among other things,
the scope of the review, barriers and facilitators of the
integration of CAM strategies in conventional medicine, and
future research activities on the CAM contribution to reduce
antibiotic use were discussed. This group and some other
CAM experts were also invited to give their input to draft
versions of the article.
2.6. Analyses. The aim of the qualitative analyses of this
narrative review is to map the relevant themes and to provide
a first broad overview of the studied domain. As a result, the
review does not provide an exact, narrow focused overview
of the state of science of each of the subareas (concepts,
prevention, treatment per indication) as is done in a scoping
review, it does not include all relevant articles if this is
not necessary for the mapping purpose, and it does not
judge the methodological quality of the scientific evidence
of studies on CAM prevention and treatments for specific
indications (e.g., assessment of the methodological quality
of RCTs with GRADE or of systematic reviews with the
AMSTAR 2 checklist), as is done in a systematic review.
3. Results
3.1. Search Results. See Figure 1.
3.2. Worldview Aspects of CAM and Conventional Medicine
Relevant for Prevention and Treatment of Infections and the
AMR Problem. Worldviews are frameworks of meaning and
meaning-making that shape how individuals perceive partic-
ular issues and their possible solutions and that influence the
willingness of individuals to participate in these worldview-
related solutions [14]. Medical systems are based on specific,
often implicitly handled, worldviews that shape concepts of
health, disease, and treatment that in their turn underlie
preventive, diagnostic, and treatment strategies applied in
clinical practice (Figure 2). A good understanding of the
similarities and differences between conventional medicine
and CAM worldviews and related concepts, and infection
prevention and treatment strategies is expected to contribute
to integrate the best of both worlds [15] and is therefore here
shortly described.
The main worldview in conventional medicine is the
biomedical model. Treatment within this model is mainly
oriented at “fighting the disease” both in prevention and
treatment, in order to regain the default situation of health
[16].
CAM systems (e.g., anthroposophic medicine, ayurveda,
homeopathy, traditional Chinese medicine, naturopathy) are
whole medical systems, complete systems of theory and
practice that have evolved independently over time in dif-
ferent cultures and apart from conventional medicine or
western medicine [15, 17, 18]. In daily clinical practice, based
on the nonatomistic holistic worldview and related health
and disease concepts, CAM stimulates a health promotion
oriented lifestyle (prevention) and treats patients with the
aim of strengthening or supporting the self-healing or self-
regulating ability of the human organism [19] to cope with
diseases [20–26].
The differences in worldview and related concepts of
health and disease are also expressed in the differences in the
main prevention and treatment strategies for infections. Con-
ventional medicine historically was and is (more) focused on
fighting disease, more or less implicitly regarding health as
the absence of disease. CAM historically focused (more) on
health promotion strategies.
The main conventional preventive strategies are vaccina-
tions, hygiene, improving nutrition, and isolation measures
[3]. Their aim is respectively to produce immunity and
to prohibit contact with microorganisms. The main CAM
preventive strategies are lifestyle changes/interventions and
medical measures/interventions that strengthen resilience
[27]. Their aim is to improve the physiological ability to self-
manage and adapt to infections.
The main conventional treatment strategies are antimi-
crobial treatments that kill or reduce the growth of microbes
and reduce disease-related symptoms, like discomfort of fever
and pain. The main treatment strategies of CAM are the
medicinal and nonpharmaceutical treatments that support
the organism to overcome the infection by itself by means
of strengthening the self-regulating abilities of the organism
(“changing the host’s capacities”).
Both in conventional medicine and in CAM, there are
currently developments that are aimed at integrating the best
of both worlds of fighting disease and health promotion
approaches [15, 22].
3.3. What Is the Evidence That Supports the Hypothesized
CAM Contributions?
3.3.1. Health and Health Promotion Concept. The key ele-
ments of the CAM concepts of health are the following: (1)
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Figure 2: Worldviews, concepts, and clinical practice.
health is the result of a self-regulating inner activity, and (2)
health is aimed at restoring wholeness of the organism and
balance within or between the functions of body, soul, and
spirit [24, 65]. In agreement with the health concept, health
promotion can be logically defined as the process of enabling
individuals, groups, or societies to increase control over, and
to improve, their physiological, psychosocial, and spiritual
(meaning in life) health [66]. Health promotion thus aims to
improve the development and quality of the self-regulating
abilities on these levels and aims to restore balance between
opposite functions.
In 1948, the World Health Organization (WHO) defined
health as ‘a state of complete physical, mental and social well-
being and not merely the absence of disease or infirmity’. In
2011, Huber et al. [67] redefined health as ‘the ability to self-
manage and adapt’. This concept is in line with current other
concepts of health (e.g., resilience, salutogenesis), emphasiz-
ing the role of self-regulating abilities in the physiological,
psychosocial, and ‘meaning in life’ level as internal resources
of the human being to remain or become (more) healthy
[22, 68].
One of the mechanisms of acquiring health by self-
regulation is the active balancing of opposite functions in the
organism, which is increasingly described in the literature
on, for example, apoptosis [69] (programmed cell death as
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an opposite function to ongoing cell division in organisms),
wound healing [70], and chronobiology [71]. Imbalances of
one of the two opposite functions is related to disease states
[72].
In conclusion, we state that there is some evidence that
CAM health and health promotion concepts are internally
consistent and increasingly in agreement with current health
conceptualization in conventional medicine. Their degree
of agreement with empirical facts is described in the next
paragraphs on health promotion oriented prevention and
treatment strategies.
3.3.2. Less Prescription and Consumption of Antibiotics. Sev-
eral, mostly observational, studies (Table 1) support the
hypothesis that practices of doctors who practice both CAM
and conventional medicine compared to their conventional
colleagues have lower antibiotic prescription rates (measured
as past use, antibiotics use ever, in the first 12 months of life
and after 12 months of life, consumption, prescription rates)
and their patient groups have lower antibiotic consumption
rates, although in these studies selection bias (e.g., patients
that do not want antibiotics may choose more often a CAM
doctor) cannot be ruled out.
3.3.3. Effects and Safety of Prevention Strategies. The main
CAM prevention strategies are lifestyle changes/interven-
tions and medical measures/interventions that strengthen
and/or support the physiological ability of the organism to
self-manage and adapt to infections. Prevention CAM strate-
gies are aimed at (1) reducing stress, insomnia, depression,
and anxiety (that are all associated with higher susceptibility
to infections), (2) promoting healthy diets and physical
exercise (reducing both the risk of infectious diseases), (3)
supporting the fever reaction of the organism to infections
(to enable the organism to overcome the infection by itself),
and (4) preventing infections with natural products.
Chronic Stress, Insomnia, Depression, and Anxiety Associated
with Higher Susceptibility to Acute Infectious Illness. Chronic
stress suppresses or dysregulates innate and adaptive immune
responses by altering the Type 1–Type 2 cytokine balance,
inducing low-grade chronic inflammation, and suppress-
ing numbers, trafficking, and function of immunoprotec-
tive cells. Chronic stress can suppress protective immune
responses and/or exacerbate pathological immune responses
[73, 74]. Higher reported stress levels [75, 76], short sleep
duration (< 6 or 7 hours/night) and poor sleep continuity
[77, 78], depression [79], and anxiety [80] are all associated
with higher susceptibility to acute infectious illness (e.g.,
common cold, pneumonia).
Chronobiology and General Physiological Recovery. Chrono-
biology research has demonstrated that rhythms are present
in the whole human organism and all its cells and that they
are responsible for the ordered balancing in time between,
for example, degenerative and regenerative physiological pro-
cesses, performance and recovery, sympathetic and parasym-
pathetic activity, work and relaxation, and wakefulness and
sleep [71, 81]. Biorhythms are important for recovery in
several physiological functions. The speed of recovery differs
between biorhythms in the range from very quick recovery
(membrane recovery in milliseconds), local tissue recovery
in minutes, moderately quick recovery of fatigue by sleep-
ing in 24 hours, until longer recovery periods (vegetative
recovery/self-healing (weeks) and trophic/plastic adaptation
and growth (months)) [82].
PreventiveCAMStrategies. Several preventiveCAMstrategies
aim to reduce stress, insomnia, depression, and anxiety that
are linked to an increased susceptibility to infections [77–
80]. CAM prevention includes often promotion of a rhythmic
lifestyle [71, 82] in order to support general physiologi-
cal recovery. Meditation programs can reduce the negative
dimensions of psychological stress [83–87]. Mindfulness is
currently recommended as a useful method for improving
mental health and reducing symptoms of stress, anxiety, and
depression [88, 89]. Regular sauna visits, both in children
and adults, reduce the frequency and severity of influenza
infections, and the incidence of the common cold [90].
In athletes (intermediate trackers compared to untrained)
the immune system is more stimulated with an increased
number of white blood cells, lymphocyte, neutrophil, and
basophil counts after the sauna session. The main working
mechanisms of becoming more resilient (among others to
infections) after sauna are optimization of temperature and
circulation regulation of skin and mucous membranes, vege-
tative stabilization with decrease of sympathetic tone (stress
reduction), stimulation of nonspecific resistance parameters,
and strengthening the antioxidative protection potential and
thus the defense against free radicals [91]. Two RCTs demon-
strated that balneotherapy is beneficial for stress and fatigue
reduction in comparison with music or no therapy group
[92] and reduces distress by reducing the health risk posed
by distress (by 26%), by increasing the health resources (by
11%), and by reducing probability of general health risk (by
18%) [93]. Based on a systematic review of 23 articles [94]
it was concluded among others that the administration of
various forms of therapeutic massage exerted a reduced risk
of neonatal sepsis and reduced neonatal stress in very preterm
neonates, based on increased vagal activity, increased gastric
activity, and increased serum insulin levels. A review of 14
studies on the effects ofmassage on older people in residential
care settings concluded that older people perceive positive
effects of massage on factors such as pain, sleep, emotional
status, and psychosocial health [95]. Tai-chi is associated
with improvements in psychological well-being including
reduced stress, anxiety, depression, and mood disturbance
and increased self-esteem [96]. Steiner or Waldorf school
education is associated with lower cortisol levels of children
[97–99] and better adjustment to higher education (less
anxiety and depression symptoms, greater life satisfaction
and academic achievement) compared to children from
conventional schools [100]. In Steiner or Waldorf schools,
knowledge of biorhythms is applied in the design of the
curriculum [101].
Changes of diets are related to rapid changes of the
human gut microbiome [102] that is related to the human
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Table 1: Studies on prescription and consumption rates of antibiotics in CAM practices and in families with an alternative lifestyle.
Study type Results Study characteristics
Cross-sectional study comparing
children from anthroposophic
families and children with a
non-anthroposophic lifestyle [28]
Past use of antibiotics:
(i) anthroposophic children: 52%
(ii) non-anthroposophic children: 90%
(odds ratio (OR): 0.62, 95% CI: 0.43 - 0.91)
N = 295 anthroposophic children and 380
non-anthroposophic children, age 5-13
years.
Sweden
Cross-sectional study comparing
children from anthroposophic
families and children with a
non-anthroposophic lifestyle [29]
Antibiotics use ever, in the first 12 months of
life and after 12 months of life:
(i) all significantly lower in children with an
anthroposophic lifestyle (p < 0.001)
N = 6.630 children, age 5-13 years (4.606
from Steiner schools and 2.024 from
reference schools) in 5 European countries
(Austria, 11%; Germany, 39%; The
Netherlands, 22%; Sweden, 9%; Switzerland,
20%)
KOALA Birth Cohort Study
comparing families with an
alternative and a non-alternative
lifestyle [30]
Families with an alternative lifestyle:
(i) antibiotic use was less frequent (13.8% vs.
24.1%) (p-value not presented)
N= 2.343 conventional children and 491
alternative lifestyle children.
The Netherlands
Observational study on prescribing
practices of anthroposophic
medicine (AM) doctors in the
treatment of upper respiratory tract
infections [31]
Prescription rate for antibiotics (6.3%) was
well below the German average
21.818 prescriptions for 12.081 patients
(73.7% children) with 19.050 cases of URTI
were analysed.
Antibiotics were given in 6.3% of cases
(minimum: common cold 1.9%, maximum:
tonsillitis 24.3%).
Germany
Prospective, non-randomised
comparison of outcomes in patients
self-selected to anthroposophic or
conventional therapy under
real-world conditions [10]
5.5% of the patients in the AM group and
33.6% in the conventional group received
antibiotics (p < 0.0001)
29 primary care practices (Austria,
Germany, Netherlands, UK and USA). N=
1.016 outpatients, age ≥ 1 month, consulting
an anthroposophic (N = 715) or
conventional physician (N = 301) with a
chief complaint of acute (≤ 7 days) sore
throat, ear pain, sinus pain, runny nose or
cough
Prospective, non-randomised
comparison of outcomes in patients
self-selected to anthroposophic or
conventional therapy under
real-world conditions [32]
5.5% of the patients in the AM group and
25.6% in the conventional group received
antibiotics (p < 0.001)
N = 529 children <18 years from Europe
(Austria, Germany, Netherlands, and UK) or
USA with acute respiratory or ear infections
Observational study on the
treatment of patients with upper
respiratory tract infections:
homeopathic GPs vs. conventional
GPs [33]
Significantly lower consumption of
antibiotics (OR=0.43, 95% CI: 0.27-0.68) in
the homeopathic patients group
N = 518 adults and children with URTI
(79.3% rhinopharyngitis).
France
Randomized trial, children 6
months to 11 years old, diagnosed
with AOM and managed with a
delayed antibiotic approach,
randomized to standard therapy
alone or standard therapy plus a
homeopathic ear drop preparation
[34]
Significantly less antibiotic use in the
homeopathic group (26.9% vs. 41.2%)
(p-value not presented)
N = 456 patient visits were compared: 281
received homeopathy, 175 received
conventional medicine.
Germany, Switzerland, Austria, USA
Observational study among parents
of children [35]
Use of homeopathic products not associated
with decreased antibiotic consumption
(adjusted OR = 1.02, 95% CI: 0.84 - 1.24).
N = 9.723 parents of children, age: 3–4.5
years.
United Kingdom
health and disease status. Currently probiotics, prebiotics,
and polyphenols are among the most well established dietary
strategies available for modulating either the composition
or metabolic/immunological activity of the human gut
microbiota [103]. Several “normal” diet ingredients are able to
positively influence the immune system [104]. A systematic
review and meta-analysis with 14 included studies demon-
strated that, overall, flavonoid supplementation decreased
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URTI incidence by 33% (95% CI: 31%-36%) compared with
control, with no apparent adverse effects [105]. In a mice
model, it was demonstrated that the gut microbiota plays
a protective role in the host defense against pneumococcal
pneumonia [106]. Polyphenols appear to protect athletes
from virus infections following rigorous exercise [107].
A systematic review of 28 articles demonstrated that
exercise has considerable effects onmarkers of cellular aspects
of the immune system [108]. Current theories regard exercise
as a powerful stimulus of immune function [109]. Regular
exercise has been shown to improve neutrophil microbicidal
functionswhich reduce the risk of infectious disease, andmay
be related to improved vaccine responses [110].
Fever induction is the result of a fine interplay between
the innate immune system and the neuronal circuitry within
the central and peripheral nervous systems. It results in
the increase of metabolic rate and the enhancement of
immune-protective mechanisms (both innate and adaptive)
during infection [111]. A small rise in body temperature
inhibits bacterial and viral replication (creation of a thermal
restriction zone) [111, 112], while at the same time accelerating
the immune response (increasing the mobility of polymor-
phonuclear cells, increasing phagocytosis and T-helper cell
adherence, and prevention of lymphocytes cell reduction
(CD4 T cells and B cells activity)), and attenuating the
immune response/protection against the collateral damage
(increased heat shock protein causing a decrease of NF-
𝜅B, reduced TNF𝛼, and reduced IFN𝛾) [113]. In men, early
acute respiratory distress syndrome (ARDS), an elevated peak
temperature in the first 24 hours in ICU in critically ill
patients with an infection [114], is associated with improved
survival rates (adjusted OR: 0.56, 95% CI: 0.48–0.66). It is
now evident that antipyretic treatment (paracetamol, aspirin,
or ibuprofen) does not prevent seizures [115]. A recent review
and meta-analysis demonstrated that antipyretic treatment
does not prolong the fever or illness, but may alter inflam-
matory processes, especially in the early phase during which
the immune response develops. It may lead to a reduction
of the initial adaptive response. Antipyretic treatment has
been shown to increase the spread of infection and prolong
influenza, chicken pox, and common colds at the population
level and may increase both the rate and duration of viral
shedding, further increasing the pathogen’s transmission
rate; this effect has been shown experimentally for influenza
in ferrets. A higher transmission rate in general will lead
to larger epidemics and hence to greater morbidity and
mortality [116].
Finally, prevention of infections is achieved by use of
natural products, for example, prevention of wound and
gastrointestinal infections by apitherapy and respiratory tract
infections by probiotics [53, 117, 118].
3.3.4. Effects of Treatment Strategies. Evidence of the effects
of CAM medicinal treatment strategies comes from 12
Cochrane reviews (Table 2), 16 non-Cochrane reviews
(Table 3), 15 clinical studies (Section 3.3.4 (2)), and 20
studies on traditional use and in vitro studies (Section 3.3.4
(3)). Systematic reviews were categorized per indication
(respiratory tract infections (Cochrane reviews (CRs): 7,
Non-Cochrane reviews (NCRs): 13); urinary tract infections
(CRs: 2, NCRs: 1); and other infections (CRs: 3, NCRs:
0). In addition the results of two NCRs on antibiotic-
associated diarrhoea were described. Clinical studies
were categorized per indication: acute respiratory and ear
infections (observational studies: 2), otitis media (RCT:1,
observational study: 1), infected wounds and MRSA (RCTs:
4), and other infections (RCTs: 7, observational studies: 2).
The Cochrane and non-Cochrane reviews demonstrate
that someCAMtreatment strategies for respiratory infections
(both children and adults) are promising and that some
have been shown to be effective in systematic reviews. CAM
treatment strategies for other infections such as urinary tract
infections (adult women) and skin infections are promising,
but more rigorous research is necessary to provide high
quality evidence.
(1) Other Non-Cochrane Reviews. See Table 3.
(2) Individual Clinical Studies. There are many other CAM
treatments for infections which have been studied in a
clinical trial, but for which no systematic review has yet been
completed.
Acute Respiratory and Ear Infections. An international, mul-
ticenter, cohort study, comparing homeopathic and conven-
tional treatment of acute respiratory and ear complaints
in a primary care setting with 1.577 patients (857 received
homeopathic and 720 conventional treatment), demonstrated
that homeopathic treatment was not inferior to conventional
treatment. More statistically significant favorable results for
homeopathy were as follows: onset of improvement within
the first 7 days after treatment was significantly faster upon
homeopathic treatment both in children and adults, and
adverse drug reactions occurred more frequently in adults
of the conventional group than in the homeopathic group
[119]. A prospective observational study comparing anthro-
posophic (AM) and conventional treatment of children with
acute respiratory or ear infections under routine primary care
conditions demonstrated that AM treatment was associated
with much lower use of antibiotics (5% vs. 26%, during
the four-week follow-up) and also much lower use of anal-
gesics/antipyretics (3% vs. 26%) and was safe. AM patients
demonstrated somewhat quicker symptom resolution and
higher caregiver satisfaction [32].
Otitis Media. There is some evidence that Juzen-taiho-to, a
Kampo or traditional Japanese herbal medicine, is effectively
preventing recurrent acute otitis media (AOM) in children
[120]. A prospective nonrandomized, comparative study
underlined these results in the treatment of children with
chronic otitismediawith effusion.The frequency of antibiotic
use was significantly less with the integrative concept using
integrative-anthroposophic treatment (17.9% vs. 82.9%) [121].
Infected Wounds and MRSA. Tea Tree Oil (TTO) is an essen-
tial oil derivedmostly from the leaves and terminal branchlets
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of the Australian native plant Melaleuca alternifolia from the
Myrtaceae family [122]. Although no Cochrane systematic
review has been conducted yet with regard to effects of TTO
on MRSA infections, there is low quality evidence that 10%
TTO soap significantly reduces MRSA quantity in infected
wounds. TTO has been studied as an alternative treatment
option for MRSA infections [123–126]. In a RCT a 10% TTO
cream and 5%TTObodywashweremore effective in clearing
MRSA on skin compared with 4% chlorhexidine gluconate
soap and 1% silver sulfadiazine cream [124].
Other Infections. There is some evidence that CAM use
in patients with cancer is associated with a reduction in
hospitalizations and requirements for antibiotics [127]. Tri-
als of complementary interventions (vitamin A, probiotics,
cranberry, nasturtium, and horseradish) for prevention of
recurrent urinary tract infection in children generally gave
favorable results but were not conclusive [128]. Herbal ther-
apies appeared to be at least as effective as rifaximin for
resolution of small intestine bacterial overgrowth and as
effective as triple antibiotic therapy for SIBO rescue ther-
apy for rifaximin nonresponders [129]. Long-term vaginal
administration of Lactobacillus rhamnosus appears to be
a useful complementary approach in the management of
bacterial vaginosis [130]. A RCT, comparing the effects of
vaginal cream with thyme and garlic and Metronidazole
vaginal gel on treatment of bacterial vaginosis, demonstrated
that both treatments were equally effective [131].
(3) Traditional Use and/or In Vitro Studies. Many CAM
treatments have not been studied (at all or not for specific
indications) in clinical studies with humans. They have only
a status of long traditional use and/or have demonstrated
antimicrobial effects in vitro. We describe here a very small
selection of examples without any claim on completeness in
selecting the examples. The importance of describing them
here is that, given the urgent need for alternative, nonan-
tibiotic treatments, this group of CAM treatments might be
a source of development of new nonantibiotic alternatives.
Positive experience during long periods of traditional use
and/or positive results of in vitro studies provide a reason to
study these remedies in clinical studies with patients.
Anemarrhena asphodeloides had been used in China,
Japan, and Korea for thousands of years and demonstrates
both antimicrobial and antiviral activities in vitro [132, 133].
Asparagus racemosus might be an alternative to antibiotics
during UTI infections [134, 135]. Diodia scandens and Phyl-
lanthus amarusmight be effective againstMRSA [136], extract
220D-F2 from the root of Rubus ulmifolius can be used to
inhibit S. aureus biofilm formation to a degree that can be
correlated with increased antibiotic susceptibility without
toxic effects on normal mammalian cells [137], Woodfor-
dia fruticosa appears to be effective against Pseudomonas
pseudoalcaligenes and Gram-negative bacteria [138, 139], a
review identified 255 (70% of 365) plant species from a wide
range of families that have shown antimycobacterial activity
[140], and protocatechuic acid (PCA, 3,4-dihydroxybenzoic
acid) is a phenolic compound found in many food plants
that demonstrates antimicrobial activities and also exerts
synergistic interaction with some antibiotics against resis-
tant pathogens [141]. Asparagus racemosus demonstrated
positive effects in vitro against several UTI Gram-negative
and Gram-positive pathogens [135]. Apitherapy is used in
many traditional medical systems, among others, for the
prevention of respiratory infections [142]. Natural honey
demonstrated antiacanthamoebic properties [143], antibac-
terial effects [144], and antibiofilm effects against S. aureus
[145] in wound healing. Melissa officinalis L. demonstrates
both antibacterial and antifungal effects [146]. Several studies
describe a list of promising CAM treatments for several
infections, based on clinical experience and/or in vitro studies
[147–150].
Andrographis paniculata has already been shown in clini-
cal trials to be effective for respiratory infections (see above).
In addition to this it may be effective against other infections.
It is currently used in ayurveda, homeopathy [151], and
TCM [152]. In vitro studies demonstrated dose-dependent
antibacterial effects ofA. paniculata: against E. coli, Klebsiella,
Staphylococcus and Pseudomonas [153], Salmonella, Shigella,
Gram A Streptococci, S. aureus, MRSA, Pseudomonas aerug-
inosa [154], Salmonella typhimurium, E. coli, Shigella sonnei,
Streptococcus pneumonia, Streptococcus pyogenes, Legionella
pneumophila, and Bordetella pertussis [155]. However in one
study no activity against E. coli or Klebsiella pneumoniae was
detected [154].
Pelargonium sidoides has already been tested in clinical
trials for respiratory infections (see above) but may also
be helpful in the treatment of other infections. Its tradi-
tional use was for the treatment of diarrhoea. Mechanistic
evidence from a review in 2014 [156] concluded the fol-
lowing: ‘experimental results from in vitro studies indicate
that bioactive phytochemical constituents of Pelargonium
sidoides may not possess a direct antimicrobial effect, but
instead act by interfering with microbial binding to host
cell receptors, inhibition of key enzymes and the production
of antimicrobial effector molecules such as nitric oxide and
interferons (IFNs) by the host cells.’ However, other in vitro
studies did demonstrate growth inhibition of Escherichia
coli, Shigella sonnei, Staphylococcus aureus OK2a and S.
aureus ATCC6538, Salmonella typhi, S. typhimurium, Shigella
flexneri, and Staphylococcus aureus OK2b [157].
Several studies also demonstrate the potential of treat-
ment with natural products of viral infections, for example,
licorice for several viral infections [158].
(4) Nonpharmaceutical Interventions.There is some evidence
that acupuncture is effective in pain reduction of acute sore
throat [159, 160]. Blue light demonstrates bactericidal effects
in vitro and in vivo [161–163]. Based on the expertise of
anthroposophic nurses, there is some practice-based evi-
dence that external applications with essential oils may have
effects on symptom relief [164].
3.3.5. Safety. General side effects of antibiotics use are
antibiotic-associated diarrhoea (AAD) that happens in 5-39%
of patients that are prescribed antibiotics [63] and candidiasis,
obesity (associated with childhood use of antibiotics before 2
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years) [165–169], allergies (in 5-10%of all patients [170] and in
10-30% of hospital patients [171]), increase of irritable bowel
syndrome (IBS), and irritable bowel disease (IBD) symptoms
[172]. In the treatment of AOM for every 14 children treated
with antibiotics, one child experienced an adverse event (such
as vomiting, diarrhoea, or rash) that would not have occurred
if antibiotics had been withheld [173].
According to a systematic review of results reported in
RCTswith 111 studies of a single herb and 133 ofmultiple herbs
with a total of 15,441 participants, herbal treatment may be
considered as safe: ‘There were 480 cases (3.1%) of adverse
events (344 for single, 136 for multiple herb studies; p< 0.01).
A total of 259 cases reported blood test abnormalities, includ-
ing five cases of abnormality in hepatic functional enzymes.
The most frequently reported adverse event was digestive
symptoms (44.3%), followed by nervous system symptoms
(17.3%) and behaviors such as loss of appetite (16.3%).’ [174]
However, a few herbal treatments have been associated
with severe adverse events [175–177]. In reaction to these
problems, pharmacovigilance systems have been established
in the main producing countries of Chinese herbals [178]
and Ayurvedic herbals [179], and quality standards for these
medicinal products (MPs) have been improved [180, 181].
Other concerns are the inadequate knowledge of their mode
of action, potential adverse reactions, contraindications, and
interactions with existing orthodox pharmaceuticals and
functional foods [182, 183].
Adverse reactions to homeopathic and anthroposophic
MPs are infrequent and usually of mild to moderate severity,
and anaphylactic reactions occur but are very rare [15, 57,
184].
4. Discussion
Given the mismatch between the urgent need for nonantibi-
otic strategies and the lack of use of CAM strategies embed-
ded in current conventional policies and clinical practice,
we performed a narrative review, based on searches in three
databases (PubMed, Embase, and the Cochrane Database
of Systematic Reviews) with a specific, limited set of search
terms and input from CAM (research and clinical) experts,
to explore and map what is known about the contribution
of CAM health and health promotion concepts, infection
prevention, and infection treatment strategies to reduce
antibiotic use. This review has found significant evidence to
support the safety and effectiveness of a range of CAM treat-
ments for respiratory infections, based on many systematic
reviews. It is now important to assess how this information
can be used to recommend alternatives to antibiotics and so
avoid unnecessary use of antibiotics in clinical practice. For
other types of infection (such as urinary infections and skin
infections) there are some promising clinical trials, but more
research is needed before recommendations can be made.
4.1. Strengths and Limitations. The main strength of this
review is the broad overview on this domain: the differ-
ences between conventional medicine and CAM regarding
worldview, health (promotion) concepts, related prevention
and treatment strategies for infections, and supporting evi-
dence. This broad scope may contribute to providing a more
transparent view on the differences between conventional
medicine and CAM and on the possible contribution of CAM
strategies. The promising results may also provide a broader
interest in conventional medicine to study the contribution
of CAM to the reduction of antibiotic use, and provide
interest in the professional integration of the best of both
worlds of CAMand conventional medicine in prevention and
treatment strategies of infections, in line with, for example,
the current ‘Traditional Medicine Strategy: 2014-2023’ of the
World Health Organization (WHO) [12].
The review has also several limitations. The first one
is that it is a narrative review that is aimed at exploring
relevant themes and at providing a first broad overview of the
studied domain. The review thus does not provide an exact,
narrow focused overview of the state of science of each of
the subareas (concepts, prevention, treatment per indication)
as is done in a scoping review, and it does not judge the
methodological quality of the scientific evidence of studies
on CAM prevention and treatments for specific indications,
as is done in a systematic review. A second limitation is
that the number of databases searched was limited to three
(PubMed, Embase, Cochrane Database of reviews), that a
limited number of search terms was used, that the acquired
additional recordswere not collected in a systemizedway, and
that input was given by a selected group of CAM research
and/or clinical experts, which might have led to a selection
regarding the content provided as input. A third limitation
is that the quality of the studies was often low. For example,
many of the studies on prescription of antibiotics (may have)
used self-selected samples. It is therefore not obvious that
it would be possible to reduce use of antibiotics simply
by transferring patients from conventional to integrative
doctors, because the reasonmay be that patients self-selecting
to go to CAM doctors are less likely to demand antibiotics.
4.2. Medical and Methodological Barriers and Facilitators
of the Implementation of CAM Strategies into Conventional
Medicine. Besides, in many cases, the absence of high quality
evidence, the implementation of CAM prevention and treat-
ment strategies into conventional medicine is hindered by
several other medical and methodological barriers.
Whereas CAMmodalities were tolerated in clinical prac-
tice in many western countries until the end of the 20th cen-
tury, they are increasingly becoming scientifically criticized
[15, 185]. According to many scientists, CAM treatments are
justified with prescientific or unscientific paradigms that are
not in agreement with currently accepted medical theories.
Therefore, on theoretical grounds, it is their and others’
opinion that CAM must not be integrated with conventional
medicine [186–188]. A second group of barriers concerns
the quality of CAM prevention and treatment strategies. The
image of CAM, in conventional science and medicine, is
often that there is no high quality evidence of specific effects
of CAM strategies for conventional indications as tested in
clinical studies and analyzed in systematic reviews and meta-
analyses [186]. In addition, there are concerns regarding the
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safety and drug interactions of CAM treatments [189–191],
because some medicinal products have been associated with
repeated, severe adverse reactions [192, 193]. Other concerns
are environmental contaminations (e.g., air pollution, soil
contaminations), cultivation practices (e.g., pesticides, fungi-
cides, microorganisms, endotoxins), manufacturing proce-
dures (e.g., microorganisms, endotoxins), and inappropriate
use [194, 195].
Another group of barriers concerns implementation of
CAM strategies. First, whereas some conventional guidelines
are still based on clinical expertise and/or lower level of
evidence (e.g., in pediatrics and surgery), input for guidelines
from CAM based on clinical expertise and/or lower level of
evidence is not easily accepted, based on the described nega-
tive image of CAM. Secondly there are regulatory barriers. In
essence, although European regulatory systems are available
for homeopathy and herbal medicines, they currently do not
match the specific features of whole medical system products
with regard to assessment of quality [196], effectiveness
and safety, and handling of multicomponent products [15].
Thirdly, the available evidence and knowledge on preven-
tion and treatment strategies are not easily accessible for
the target populations (e.g., doctors, pharmacists, patients)
[197]. Fourthly, although many patients already use CAM
MPs [198, 199] and shared-decision making is promoted in
clinical practice, many doctors do not want to prescribe
CAM alternatives for antibiotics, due to patient pressure
to prescribe antibiotics [200–202], fear of ineffectiveness of
CAM treatments [203], lack of knowledge onCAM in general
[204], insufficient information on effectiveness and safety,
(assumed) insufficient regulation of herbal practitioners, con-
cerns about herbal quality control and potential herb–drug
interactions [205, 206], and a lack of communication between
doctors and patients about this topic [204, 207].
An important methodological barrier for CAM is that
methodologies that are currently used to acquire high quality
evidence (RCTs, systematic reviews, and meta-analyses of
RCTs) often do not match CAM, so-called whole medical
system, interventions. The current golden standard of EBM,
the double-blind, placebo-controlled RCT, is often not appli-
cable to test efficacy and effectiveness of a CAM intervention
due to its complexity [208, 209]. Furthermore there are
significant regulatory barriers to conducting clinical trials
of complex or individualized mixtures of herbal medicines.
CAM treatments for conventional indications are often indi-
vidualized based on additional CAM diagnoses, are aimed
at restoring balances rather than symptom reduction, often
contain different treatments as part of a complex intervention
(multimodal), and are system effects and health promotion
oriented. As a result of this mismatch between demanded
methodologies and CAM interventions, there is a lack of
RCTs. And the available RCTs with protocolled interventions
might lead to false-negative results (meaning that in reality
the treatment has (larger) beneficial effects but these are
not captured in the research study), because of the lack
of individualization. Therefore, CAM researchers argue that
there is a need for additionalmethods, e.g., pragmatic studies,
observational studies, a mix of qualitative and quantitative
studies, and n=1 studies, in order to meet the complex-
ity of CAM interventions [210]. In addition, a “reversed
research strategy” for assessing CAM has been suggested,
starting with studies of the context, paradigms, philosophical
understanding, and utilization, then subsequently the safety
status of the whole system, comparative effectiveness of the
whole system, specific efficacy of components, and finally the
underlying biological mechanisms [78, 107]. A second barrier
is that there is a lack of structural funding of research on
CAM prevention and treatment strategies in many countries
(although in China the research on TCM is increasingly
structurally funded), with a sponsorship bias as a result [211].
Most of CAM is not patentable and not profitable, has little
lobby, and is complicated and multifactorial, and therefore
research is underfunded.
On the other hand, there are also several facilitators for
the integration of CAM prevention and treatment strategies
for infections. First of all, the position of the patient in health-
care is increasingly important (as expressed in developments
like, for example, shared-decision making, patient reported
outcomes, and experiences) and CAM is increasingly used
and demanded by patientsworldwide [43, 207, 212]. Secondly,
the increasing burden of the global AMR problem opens
opportunities for CAM alternative prevention and treatment
approaches as expressed in a NHS funded study on CAM
treatment of UTI [213] and a EU funded European research
network for CAM researchers on infections [214]. Thirdly,
the CAM concept of health promotion is increasingly in
agreement with conceptualization of health in conventional
medicine [66, 67, 215]. CAMprevention and treatment health
promotion strategies are thus not, as often assumed, justified
with a prescientific or unscientific paradigm, but are based
on theories that are increasingly accepted in conventional
medicine. Fourthly, there is a growing scientific interest in
and knowledge of systems biology/systems and personalized
approaches in conventional science and medicine, which
makes it easier to accept the CAM systems approaches [22].
Fifthly, there are positive examples of the integration of
CAM strategies, especially in low-income countries [216],
that can result in more confidence in CAM. Sixthly, there
is an increasing interest in the delayed prescription strategy,
which fits with the CAM treatment strategy; during the
delayed prescription period patients can use CAM treat-
ments. Reduced antibiotics prescription for uncomplicated
infections, without additional CAM treatment, is already
relatively safe with only a very slight increase in the incidence
of complicated infections [217, 218]. In addition, suggesting
actions parents could take to reduce their child’s symptoms
(providing parents positive treatment recommendations,
such as CAM treatments) is associated with decreased risk of
antibiotic prescribing [219]. Last but not least, there are some
good examples of positive results from CAM prevention and
treatment strategies of infections with high quality evidence
from systematic reviews/meta-analyses [51, 59, 63].
4.3. Future Research and Other Nonresearch Perspectives. The
narrative review provides concrete leads for future research
and other activities. First, in general this narrative review
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must be followed by scoping reviews and/or systematic
reviews, examining each of the subareas (e.g., prescription
rates of antibiotics) separately, providing a more complete
overview of the subarea (scoping review) and a better
judgment of the quality of the scientific evidence (systematic
review).
Although this first narrative review on CAM approaches
to reduce antibiotic use, based on a systematic search strategy,
is limited and not yet a systematic review of the literature,
it can help to structure directions and types of further
research. The following topics seem to be important for
future research in the domains that were studied here (health
and health promotion concepts, antibiotic prescription and
consumption, safety and effects of prevention and treatment
strategies). Regarding theCAMhealth (promotion) concepts,
more studies validating the health concept and exploring
and testing the health promotion working mechanisms (in
general and specific regarding infections) are necessary. With
regard to the comparison of prescription and consumption
rates of antibiotics in CAM practices and conventional
practices, more studies are needed in other integrative
primary and secondary care facilities, studies on specific
indications, and better studies controlling for selection bias.
With regard to the safety and effects of CAM prevention
and treatment strategies, more research is needed regarding
the effects and safety of CAM lifestyle/prevention strategies
on the development of resilience to infections; nosocomial
infectious diseases and resistance rates, hygiene management
in different types of hospitals (CAM vs. conventional); and
the identification, collection, and/or systematization of CAM
expert knowledge based on traditional use.
Regarding treatment, further research building on cur-
rent high levels of evidence could focus on use of CAM
as alternatives to antibiotics for respiratory infections. This
research and respective methodologies could build on the
existing systematic reviews. Decision aids and guidelines
need to be developed, piloted, and evaluated, to guide
clinicians and patients in their choice of CAM therapies.
Economic analyses will also be important to guide policy
development in this area.
For other disease areas, there is as yet insufficient evidence
for the development of guidelines or decision aids, so more
research is needed to build the evidence base with this
goal in mind. There is interesting preliminary evidence
from systematic reviews on use of CAM for treatment of
urinary tract infections and prevention of recurrent UTIs.
Further rigorous research is needed in order to find the
optimal CAM treatments for these conditions, as alternatives
for antibiotics. Another important area is the treatment of
antibiotic-resistant skin infections, such as wounds infected
with MRSA. There are some preliminary clinical trials, but
no systematic reviews in this area. Many antibiotics are
prescribed for skin infections, especially acne, yet our search
did not identify any RCTs of CAM treatments for acne.
Systematic reviews and more rigorous clinical trials are
needed to find the most effective CAM approaches for these
conditions.
In many countries worldwide a wide range of CAM treat-
ments are used daily but not well observed by the scientific
community. Such research and knowledge gaps as well as
low levels of evidence can derive from low research capacity
and /or methodological challenges. They may be relevant for
further research and for public health policy. AMR public
health policy will become more interested in learning about
the potential contribution of CAM to reduce prescription
of and demand for antibiotics. Preliminary research may
serve as a starting point with respect to some of these fields
of current CAM practice, to highlight the most promising
therapies, for example, through observational studies such as
retrospective treatment-outcome studies [220].
Finally, according to the group of CAM experts, other
issues, supporting the study of the CAM contribution and
the integration of the contribution of CAM into conventional
medicine, should be addressed in future activities: adequate
research infrastructure should be developed and optimized
(e.g., (academic) institutes, methodologies, funding) to test
CAM multicomponent and/or multimodal treatments of
infections; adequate regulatory infrastructures should be
developed to regulate multicomponent and/or multimodal
CAM treatments of infections; adequate information on
the CAM contributions needs to be provided for different
stakeholder groups (e.g., doctors, pharmacists, patients),
through the development of best practices, decision sup-
port tools, training, communication, and implementation
strategies including proposals for the integration of CAM/IM
contributions in guidelines. There need to be more studies
of patients’ demands, decision criteria, and awareness of side
effects of antibiotics and both patients’ and doctors’ percep-
tions on antibiotics and the AMR problem.There is a need for
cross-country analyses of socioeconomic factors, insurance
policies and regulation with regard to antibiotic prescription,
effectiveness of public health policies, and implementation
of guidelines as well as CAM prevention and treatment
strategies.
5. Conclusions
(1) There is some evidence that CAM prevention and
treatment strategies can lead to the prescription and
consumption of fewer antibiotics.
(2) There is some, most often low quality, evidence that
CAM prevention and treatment strategies are safe
and effective (reduction of incidence of recurrent
infections, overall symptoms and specific symptoms
of infections, symptom severity, and time to recov-
ery/sick leave).
(3) Some of the CAM treatment strategies for respiratory
infections are promising and some have been shown
to be effective in systematic reviews. Guidelines and
decision aids are needed for patients and clinicians.
(4) CAM treatment strategies for other infections such
as urinary tract infections and skin infections are
promising, but more rigorous research is necessary to
provide high quality evidence before guidelines can
be developed.
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(5) The worldview differences between CAM and con-
ventional medicine, relevant to prevention and treat-
ment of infections and the AMR problem, are the
differences between the biomedical model and the
whole medical system model.
(6) The worldview-related CAM health concepts enable
health promotion oriented prevention and treatment
of infections aimed at strengthening or supporting the
self-regulating ability of the human organism to cope
with diseases.
(7) The hypothesized CAM contributions to the reduc-
tion of antibiotic use are
(a) prevention strategies aimed at reducing stress,
insomnia, depression, and anxiety (all asso-
ciated with increased susceptibility to acute
infectious illness), promoting healthy diets and
physical exercise (both reducing the risk of
infectious diseases), supporting the fever reac-
tion of the organism (to overcome the infections
by itself), and preventing infections with natural
products;
(b) treatment strategies with natural medicinal
products.
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